At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1,220 enrolled
Drug / intervention
Candidate Influenza Vaccine GSK1247446A - 2 different formulations +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Demonstrate the Non-Inferiority of Influenza Vaccine Candidate, Compared With Fluarix™ Administered Intramuscularly in Elderly Aged 60 Years Old and Above
In Brief
A Phase 2 clinical trial evaluating Candidate Influenza Vaccine GSK1247446A - 2 different formulations and FluarixTM for Influenza. Completed, enrolled 1,220 participants across 17 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the immune response and safety of influenza vaccine candidate with or without adjuvant compared to Fluarix™ administered intramuscularly in elderly aged 60 years old and above.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesFinland, Greece
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2006
Enrollment StartMay 2006
Primary CompletionJul 2006
Study CompletionJul 2006
TodayJul 2026
First PostedMay 3, 2006
Enrollment StartMay 11, 2006
Primary CompletionJul 1, 2006
Study CompletionJul 18, 2006
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 20.2 years ago
Interventions
Candidate Influenza Vaccine GSK1247446A - 2 different formulationsbiological
Single dose, Intramuscular injection
FluarixTMbiological
Single dose, Intramuscular injection